KapposLEdanGFreedmanMS. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology2016; 87: 978–987.
2.
GoodinDSJonesJLiD. Establishing long-term efficacy in chronic disease: Use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS ONE2011; 6: e22444.
3.
GoodinDSRederATEbersGC. Survival in MS: A randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. Neurology2012; 78: 1315–1322.
4.
ShiraniAZhaoYKarimME. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA2012; 308: 247–256.
5.
TobinWOWeinshenkerBG.Stopping immunomodulatory medications in MS: Frequency, reasons and consequences. Mult Scler Relat Disord2015; 4: 437–443.
6.
OntanedaDThompsonAJFoxRJ. Progressive multiple sclerosis: Prospects for disease therapy, repair, and restoration of function. Lancet. Epub ahead of print 23November2016. DOI: 10.1016/S0140-6736(16)31320-4.
7.
MontalbanXHauserSLKapposL. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med2017; 376:209–220.
Paz SoldanMMNovotnaMAbou ZeidN. Relapses and disability accumulation in progressive multiple sclerosis. Neurology2015; 84: 81–88.
10.
O’ConnorPWGoodmanAKapposL. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology2011; 76: 1858–1865.
11.
BirnbaumG.Stopping disease-modifying therapy in nonrelapsing multiple sclerosis: Experience from a clinical practice. Int J MS Care2017; 19(1):11–14.
12.
TobinWOCostanziCGuoY. Clinical-radiological-pathological spectrum of central nervous system-idiopathic inflammatory demyelinating disease in the elderly. Mult Scler. 2017; 23(9):1204–1213.
13.
HawkinsSAMcDonnellGV.Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry1999; 67: 148–152.
